• Journal of the Ergonomics Society of Korea
• /
• v.31 no.5
• /
• pp.657-670
• /
• 2012

Background: Today, numerous telematics technologies, i.e., technologies developed by integrating telecommunications with information processing, are applied in vehicles. One such developmental application of this technology to vehicles is to increase the safety or convenience of drivers by providing them with necessary information such as warnings and information on emergencies and traffic situations. However, under certain conditions, there is a high probability of traffic accidents if the driving workload is high. Nowadays, the navigation system is frequently used in the vehicles, this system provides various information including route to the driver. But, the existing navigation systems are not only considered a driver's reaction but also provide unilaterally to the information regardless of them. Such one-side information service type may miss important information to the driver. In addition, it sometimes interferes safety driving. Objective: To solve this problem, the intelligent navigation system needs to the providing way that it checks the driver's reactions after providing information. Namely, if the driver passes the information received from the navigation, then the intelligent system provides more loudly and more frequently. Method: Therefore, in this study we introduce the intelligent navigation system that it automatically controls modality type and its strength when the driver misses or overlooks the information for their safety and entertainment and we analyze the driver's cognitive responses about the modality type and its strength. Results: To evaluate the effectiveness of the proposed system, we analyzed the reaction time and driving workload for each type of the information, modality and its strength. Also we evaluated the users' subjective satisfaction and understanding based on a questionnaire.

• Clinics in Shoulder and Elbow
• /
• v.2 no.2
• /
• pp.143-150
• /
• 1999

Purpose: The purpose of this study is to describe the characteristic clinical findings and treatment of suprascapular nerve entrapment by ganglion and to evaluate its results. Materials and Methods: Seven paitents with suprascapular nerve entrapment were evaluated on an average 13 months(range, six months to three years two months) after surgical excision and decompression. There were six males and one female. The mean age at operation was 31 years(range, 23 to 40 years), Suprascapular nerve entrapment were caused by compression of ganglion cyst in suprascapular notch or spinoglenoid notch in all cases. All patients complained of pain located over posterolateral area of the shoulder. Two patients had atrophy of both the supraspinatus and infraspinatus muscles, In four patients, only the infraspinatus muscle was involved. Muscle strength on both forward flexion and external rotation was decreased in two patients. In four patients, only external rotation was decreased. All patients underwent open excision of ganglion cyst and decompression. Results: The most dramatic effect of operation was prompt disappearance of pain in all patients. The average visual analog scale had improved from 7.2 to 0.6 point at the latest follow-up evaluation. An atrophy of the supraspinatus or infraspinatus muscle partially disappeared in four of six patients and muscle strength of forward flexion or abduction improved in all of six patients. The overall result was excellent for five patients and good for two. Conclusion: Surpascapular nerve entrapment by ganglionic cyst had clinically unique symptoms and signs on physical examination. Surgical excision is effective for symptomatic and functional outcomes. We believe that early intervention can be one of treatment modality before an irreversible damage occurs if the ganglion is large enough to compress suprascapular nerve, and to develop severe pain and muscular atrophy.

• Korean Journal of Clinical Pharmacy
• /
• v.8 no.1
• /
• pp.1-12
• /
• 1998

Rheumatoid arthritis (RA) is a common systemic inflammatory disease which DMARDS have been widely used as a treatment modality both as monotherapy and combination therapy Bucillamine, one of newer DMARDS, has recently proven its efficacy as monotherapy in the treatment of RA. The objective of this study was to compare the efficacy and the safety of bucillamine monotherapy and bucillamine plus methotrexate combination therapy in the treatment of rheumatoid arthritis. Forty-nine mild RA patients were enrolled in this prospective, open-trial and were assigned to receive bucillamine 200 mg/day (n=18) or bucillamine 200 mg/day and methotrexate 7.5-15 mg/week (n=31) orally for 16 weeks. Concomitant use of NSAID and prednisolone <5 mg/day or equivalent dose of steroid were allowed. Both monotherapy group and combination therapy group have shown significant improvement in disease activities (Ritchie index, painful joints, swollen joints, morning stiffness, grip strength, ESR, RF, CRP, patient's self assessment of pain, physician's global assessment of disease activity) from the baseline. However, there was no statistically significant difference between two groups. The adverse effects were more frequently shown in combination therapy group than monotherapy group. In conclusion, in patients with mild RA monotherapy has shown to be equally efficacious as combination therapy with less side effects.